Kymera Therapeutics, Inc.
KYMR
$24.12
$1.727.68%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -84.56% | -20.88% | 55.33% | 8.67% | 196.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -84.56% | -20.88% | 55.33% | 8.67% | 196.70% |
| Cost of Revenue | 35.58% | 25.55% | 29.36% | 15.61% | 22.81% |
| Gross Profit | -1,166.92% | -30.61% | -14.69% | -17.62% | 81.16% |
| SG&A Expenses | 14.80% | 9.45% | 22.96% | 14.40% | 22.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.18% | 21.90% | 27.85% | 15.33% | 22.69% |
| Operating Income | -318.16% | -25.41% | -17.38% | -16.72% | 50.01% |
| Income Before Tax | -392.43% | -18.20% | -8.41% | -18.64% | 58.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -392.43% | -18.20% | -8.41% | -18.64% | 58.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -392.43% | -18.20% | -8.41% | -18.64% | 58.79% |
| EBIT | -318.16% | -25.41% | -17.38% | -16.72% | 50.01% |
| EBITDA | -326.52% | -23.89% | -15.31% | -15.74% | 50.78% |
| EPS Basic | -260.29% | 9.29% | 13.45% | 2.46% | 59.24% |
| Normalized Basic EPS | -260.37% | 9.30% | 13.45% | 12.35% | 59.25% |
| EPS Diluted | -260.29% | 9.29% | 13.45% | 2.46% | 59.24% |
| Normalized Diluted EPS | -260.37% | 9.30% | 13.45% | 12.35% | 59.25% |
| Average Basic Shares Outstanding | 36.68% | 30.30% | 25.26% | 21.63% | 1.09% |
| Average Diluted Shares Outstanding | 36.68% | 30.30% | 25.26% | 21.63% | 1.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
